Aerosurf is under clinical development by Lee’s Pharmaceutical and currently in Phase II for Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Respiratory Distress Syndrome have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aerosurf’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aerosurf overview
Aerosurf is under development for the treatment of respiratory distress syndrome (RDS) and influenza A virus, H5N1 subtype infections. It is formulated as an aerosol and administered through inhalational route to premature neonates. The therapeutic candidate constitutes aerosolized KL4 surfactant and a peptide sinapultide. It is developed based on KL4 surfactant technology and aerosol delivery system (ADS) technology platform. The drug candidate was also under development for the treatment of cystic fibrosis and radiation, virus, and bronchopulmonary dysplasia in premature infants and chemical induced acute lung injury.
Lee’s Pharmaceutical overview
Lee’s Pharmaceutical is a health care provider. The company focuses on the development, manufacturing and marketing of novel therapies and contract research services. It provides products in the therapy areas of urology, cardiovascular oncology, pediatrics, dermatology, woman health, hematology, ophthalmology, dermatology, and obstetrics. The company’s products include bredinin tablets, dicoflor powder, episil oral gel, ferplex oral solution, rasilez tablets, teglutik oral suspension, cetraxal plus ear drops, intrarosa pessaries, lutrate depot, adasuve inhalation powder, teglutik oral suspension, natulan capsules, carnitene injection, readyfusor infusion pump, unidrox tablets, zanidip tablets, zingo needleless injection, among others. It also offers products in the form of gel, injection, tablets, oral solutions and infusion systems. Its products are marketed in the regions of Hong Kong, China and Taiwan. The company works in partnership with other organizations for the development and distribution rights for products across the US, Japan and other regions in Europe. It operates through its manufacturing facility located at Hefei City, China. Lee’s Pharmaceutical is headquartered in Hong Kong.
For a complete picture of Aerosurf’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
